Key Takeaways
- • InspireMD (NSPR) is scheduled to report Q2 2026 earnings on August 17, 2026 at 8:30 AM EDT, with historical earnings-date reactions showing mixed precedent (-5.79% to +0.61% over 24 hours).
- • Hedge fund activity shows mixed sentiment: Parkman Healthcare Partners LLC made the largest addition with 750,635 shares (+721.2%) valued at approximately $1.97 million in Q4 2024, while Nantahala Capital Management reduced holdings by 535,028 shares (-24.2%) valued at $1.41 million over the same period.
- • Wall Street analyst coverage remains limited but constructive, with 1 firm issuing a buy rating and 0 sell ratings on the stock as of the primary source date.
- • Recent insider trading data indicates selling pressure, with insiders disposing of 136,489 shares over the last 24 months for approximately $252,282 in aggregate proceeds.
- • Q1 2026 results showed strong operational performance with 122% revenue growth to $3.4 million and an EPS beat (-$0.16 actual vs. -$0.18 expected), though the stock declined 5.5% despite the positive surprise.
Summary
InspireMD (NSPR) will report its Q2 2026 financial results on August 17, 2026 before market open, with an investor webcast scheduled for 8:30 AM EDT. The company's most recent quarterly performance in Q1 2026 demonstrated significant operational momentum, with revenue surging 122% to $3.4 million and earnings per share of -$0.16 beating analyst expectations of -$0.18 by 11.11%. However, despite this earnings beat, the stock experienced a 5.5% decline following the announcement, illustrating a broader disconnect between operational execution and equity market reception.
Institutional investor positioning presents a nuanced picture of market confidence. Among the most significant moves in Q4 2024, Parkman Healthcare Partners LLC aggressively accumulated 750,635 shares, representing a 721.2% increase to their position valued at approximately $1.97 million. This substantial buy signals conviction from a healthcare-focused investor. Conversely, Nantahala Capital Management trimmed exposure by 535,028 shares (-24.2%) for $1.41 million, and Millennium Management reduced its stake by 68,819 shares (-17.2%) valued at $180,993. Courier Capital LLC initiated a position with 30,000 shares in Q1 2025 worth approximately $80,700, while Morgan Stanley and Northern Trust added modestly to existing holdings. Overall, 8 institutional investors increased positions while 6 decreased them during their most recent reporting periods.
From an analyst perspective, coverage remains thin with only one firm maintaining a buy rating and no sell ratings as of the primary source publication. This limited Wall Street engagement is not uncommon for microcap healthcare technology companies, though it constrains institutional visibility and potential capital flow catalysts.
Insider activity trends bearish, with company insiders selling 136,489 shares over the preceding 24-month period for aggregate proceeds of $252,282. This sustained selling pattern, though modest in absolute terms, may warrant monitoring as additional context around management's conviction in the equity at prevailing valuations.
Historical precedent for NSPR earnings announcements shows volatility, with documented 24-hour reactions ranging from -5.79% to +0.61%, suggesting investors should anticipate material price movement around the August 17 release regardless of earnings outcome.
Institutional investor positioning presents a nuanced picture of market confidence. Among the most significant moves in Q4 2024, Parkman Healthcare Partners LLC aggressively accumulated 750,635 shares, representing a 721.2% increase to their position valued at approximately $1.97 million. This substantial buy signals conviction from a healthcare-focused investor. Conversely, Nantahala Capital Management trimmed exposure by 535,028 shares (-24.2%) for $1.41 million, and Millennium Management reduced its stake by 68,819 shares (-17.2%) valued at $180,993. Courier Capital LLC initiated a position with 30,000 shares in Q1 2025 worth approximately $80,700, while Morgan Stanley and Northern Trust added modestly to existing holdings. Overall, 8 institutional investors increased positions while 6 decreased them during their most recent reporting periods.
From an analyst perspective, coverage remains thin with only one firm maintaining a buy rating and no sell ratings as of the primary source publication. This limited Wall Street engagement is not uncommon for microcap healthcare technology companies, though it constrains institutional visibility and potential capital flow catalysts.
Insider activity trends bearish, with company insiders selling 136,489 shares over the preceding 24-month period for aggregate proceeds of $252,282. This sustained selling pattern, though modest in absolute terms, may warrant monitoring as additional context around management's conviction in the equity at prevailing valuations.
Historical precedent for NSPR earnings announcements shows volatility, with documented 24-hour reactions ranging from -5.79% to +0.61%, suggesting investors should anticipate material price movement around the August 17 release regardless of earnings outcome.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.